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ABSTRACT
Objective: To explore the treatment response, tolerability and safety of once-monthly paliperidone
palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since
diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years).
Research design and methods: Post hoc analysis of a prospective, interventional, single-arm, multi-
centre, open-label, 6-month study performed in 233 recently diagnosed and 360 chronic patients.
Main outcome measures: The proportion achieving treatment response (defined as ≥20% improve-
ment in Positive and Negative Syndrome Scale [PANSS] total score from baseline to endpoint) and
maintained efficacy (defined as non-inferiority in the change in PANSS total score at endpoint
[Schuirmann’s test]).
Results: 71.4% of recently diagnosed and 59.2% of chronic patients showed a ≥20% decrease in PANSS
total score (p = 0.0028 between groups). Changes in PANSS Marder factors, PANSS subscales, and the
proportion of patients with a Personal and Social Performance scale (PSP) total score of 71–100 were
significantly greater in recently diagnosed compared with chronic patients. PP1M was well tolerated,
presenting no unexpected safety findings.
Conclusion: These data show that recently diagnosed patients treated with PP1M had a significantly
higher treatment response and improved functioning, as assessed by the PSP total score, than chronic
patients.
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1. Introduction
Long-term clinical outcomes in schizophrenia are variable but
the majority of patients will experience multiple exacerbations
and relapses.[1] A high proportion of patients are likely to
relapse if they discontinue antipsychotic (AP) treatment [2]
and relapse rates in patients continuing AP medication after
stabilization are reported as 27% over 7–12 months.[3] In first-
episode patients who were stabilized on a second generation
long-acting injectable antipsychotic treatment (LAT) for
2 years, 79% and 94% relapsed within 1 and 2 years, respec-
tively, when allowed to discontinue their treatment.[4]
Moreover, evidence shows that frequent relapses are asso-
ciated with clinical deterioration.[5–7] As such, relapse preven-
tion remains a key therapeutic aim in the treatment of
schizophrenia.[8]
Since clinical and psychosocial deterioration associated
with schizophrenia often occur within the first few years fol-
lowing the onset of the illness,[9] this early phase is a critical
period for treatment. Early and effective intervention can be
decisive in improving long-term patient outcomes.[10]
Patients with early psychosis can achieve optimal long-term
outcomes if attempts are made to overcome barriers such as
non-adherence to medication.[11] However, evidence has
shown that 42% of patients failed to collect their prescription
within 30 days of discharge, following a first hospitalization for
schizophrenia.[12]
LATs were designed as an option to address common
partial or non-adherence in patients with schizophrenia.
Meta-analyses assessing the benefits of LATs are sensitive to
research design, and results differ depending on the method
used.[13–15] Nevertheless, studies that are more reflective of
clinical practice demonstrate that the use of LATs may help to
enhance transparency of non-adherence and has been asso-
ciated with improvements in adherence,[16] relapse preven-
tion,[14,17] and reduced rates of re-hospitalization [12,17]
compared with oral formulations of APs. Thus, compared
with oral APs, LATs are likely to reduce the burden to the
patient and the healthcare system.[18] Despite the observed
benefits,[12,14,16,17] many psychiatrists are reluctant to dis-
cuss LATs with patients, possibly due to concerns regarding
patients’ perceptions of injectable APs. Many clinical guide-
lines still recommend that treatment with LATs be reserved for
patients with recurrent relapses related to partial/non-adher-
ence or for patients who have a preference for the LAT
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regimen,[1,8] while other more recent guidelines suggest con-
sidering LATs at any time, including very early stages of schi-
zophrenia.[19,20]
Altogether, growing evidence suggests that the critical
period of the disease encompasses the first few years follow-
ing an initial psychotic episode.[21–23] Therefore, it will be
important to assess the response to treatment, safety and
tolerability, and functional outcomes of recently diagnosed
versus chronic patients in routine clinical practice.
Paliperidone Palmitate Flexible Dosing in Schizophrenia
(PALMFlexS) was a large international, prospective 6-month,
open-label trial that explored treatment response, functional
outcomes, safety and tolerability in patients switched to once-
monthly long-acting paliperidone palmitate (PP1M) following
previously unsuccessful treatment with oral or other depot
APs. The patient population and the flexible dosing of PP1M
in PALMFlexS were designed to resemble routine clinical prac-
tice, compared with previous randomized controlled trials
(RCTs). The PALMFlexS study comprised samples from three
distinct patient populations: patients with non-acute schizo-
phrenia switching to PP1M from oral APs,[24] non-acute
patients switching to PP1M from other depot APs,[25] and
acute patients switching to PP1M from oral APs.[26] The data
presented here are from a subset with particular clinical inter-
est, non-acute patients switched to PP1M from oral APs stra-
tified according to the time since diagnosis as recently
diagnosed (≤3 years) or chronic patients (>3 years).
2. Patients and methods
2.1 Study design
The aim of this post hoc analysis from a single-arm, multicentre,
open-label, 6-month interventional study in non-acute but
symptomatic patients with schizophrenia previously unsuccess-
fully treated with oral APs (Clinical trials.gov number:
NCT01281527) was to explore treatment response, functional
outcomes, safety and tolerability of flexible doses of PP1M in
recently diagnosed (≤3 years) and chronic (>3 years) adult non-
acute but symptomatic patients with schizophrenia. Prior to trial
initiation, the protocol was reviewed and approved by an inde-
pendent ethics committee in all participating countries. The
study was performed in accordance with the Declaration of
Helsinki, and was consistent with Good Clinical Practice of the
International Conference on Harmonisation and applicable reg-
ulatory requirements. All patients provided their signed consent
to participate in the trial and were free to withdraw at any time.
Methods and overall results have previously been reported in
detail [24] and are briefly summarized as follows.
2.2 Patients
Patients aged ≥18 years were eligible for study enrolment if
they had a diagnosis of schizophrenia (Diagnostic and
Statistical Manual of Mental Disorder [DSM]-IV), were non-
acute but symptomatic and were switched to PP1M from an
unsuccessful treatment with a previous oral AP medication.
Participants were required to be stable (i.e. have been on the
same oral AP given for the treatment of schizophrenia in an
adequate therapeutic dose and with a change in Clinical
Global Impression-Severity [CGI-S] score ≤1 in the 4 weeks
before enrolment). Their current treatment was considered to
have been unsuccessful due to one or more of the following:
lack of efficacy (baseline Positive and Negative Syndrome
Scale [PANSS] total score ≥70 or ≥2 items scoring ≥4 in the
PANSS positive or negative subscale or ≥3 items scoring ≥4
in the PANSS general psychopathology subscale, as judged
by the investigator), lack of tolerability or safety (the pre-
sence of clinically relevant adverse effects), lack of compli-
ance or patient’s wish. Patients were categorized according
to the main reason for switching, either due to lack of effi-
cacy or due to other reasons (lack of tolerability, lack of
compliance or patient’s wish). There were no exclusions
based on body mass index (BMI). Drug abuse, specifically
nicotine, caffeine, and cannabis, is frequent in patients with
schizophrenia and therefore represents a naturalistic trait of
the schizophrenia population. A consistent, more frequent
and regular drug use as seen with intravenous drug use, i.e.
heroin and derivatives, is significantly less common in schi-
zophrenia and does not represent a naturalistic trait of schi-
zophrenia populations. Therefore, to select a more
naturalistic population within this study, we included
patients with current substance use or abuse but excluded
patients with intravenous drug use.
2.3 Treatment
PP1M was initiated at 150 mg eq on Day 1 and 100 mg eq
on Day 8 (±2 days) intramuscularly, both given in the del-
toid muscle. At initiation of PP1M, patients were tapered off
their previous oral AP, preferably within a maximum of
4 weeks. Thereafter, PP1M was administered once monthly
(±7 days) in either the deltoid or gluteal muscle, using
flexible maintenance dosages, preferably within the range
of 50 to150 mg eq, based upon the clinical judgement of
the treating physician.
2.4 Study assessments
The primary efficacy outcome for stable but symptomatic
patients switched due to unsuccessful treatment with the
previous oral AP was the percentage of patients achieving
treatment response, defined as ≥20% improvement in PANSS
total score from baseline (Day 1) to last-observation-carried-
forward (LOCF) endpoint (at 6 months or early discontinua-
tion). Maintained efficacy (defined as non-inferiority in the
change in PANSS total score at endpoint versus baseline, as
measured by means of Schuirmann’s test) was the primary
efficacy outcome for patients switched to PP1M for other
reasons.
Secondary outcomes encompassed actual values and
changes from baseline to endpoint in the following clinician-
rated scales: CGI-S; Clinical Global Impression-Change (CGI-C);
PANSS subscales and Marder factors; the Personal and Social
Performance (PSP) total score;[27] the Mini International
Classification of Functionality, Disability, and Health (ICF)
Rating for Activity and Participation Disorders in
Psychological Illnesses (Mini-ICF-APP) scale;[28,29] sleep and
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daytime drowsiness. Carer burden was measured according to
the Involvement Evaluation Questionnaire (IEQ) [30] and the
Subjective Well-being under Neuroleptics Scale (Short form)
(SWN-S) [31] and Treatment Satisfaction Questionnaire for
Medication (TSQM) [32] were completed by the patients.
Safety assessments included the recording and monitoring
of treatment-emergent adverse events (TEAEs) and measures
of alcohol and substance use (Clinician Rating Alcohol Use
Scale [CRAUS], Clinician Rating Substance Use Scale [CRSUS]).
[33] In addition, extrapyramidal motor symptoms (EPMS) were
assessed by the Extrapyramidal Symptom Rating Scale (ESRS)
total score.[34] Body weight was recorded and BMI calculated.
A threshold of ≥7% was used to determine clinically significant
weight gain or loss.[35] In this pragmatic study, there were no
obligatory protocol-based prolactin measurements, yet inves-
tigators were allowed to measure prolactin levels at any time
during the study at their own discretion.
2.5 Data analysis
The intent-to-treat (ITT) population comprised all subjects who
received PP1M at least once. LOCF endpoint analysis in addi-
tion to observed case analysis of treatment response was
performed on all ITT subjects with at least one post-baseline
assessment on any efficacy parameter. Actual values and
changes from baseline were summarized descriptively at
each assessment time point and at endpoint, and categorical
variables were summarized with frequency and percentage.
Within-group differences for both primary and secondary end-
points were tested by means of the Wilcoxon signed-rank test.
The McNemar test was used to test within-group changes in
binomial variables and between-group comparisons were
tested by means of the Wilcoxon two-sample test or Fisher’s
exact test. Safety and tolerability were evaluated throughout
the study on the safety ITT population, which comprised all ITT
patients who had at least one post-baseline observation on
any safety parameter. TEAE frequency distributions included
severity of events (i.e. mild, moderate, or severe) and causal
relationship to treatment (i.e. not related, doubtful, possible,
probable, or very likely).
3. Results
3.1 Demographics and patient disposition
The ITT population consisted of 593 patients and included 233
(39.3%) recently diagnosed and 360 (60.7%) chronic patients.
Overall, 77.7% and 72.5% of recently diagnosed and chronic
patients, respectively, completed the study (Table 1). In both
groups, the most common reason for early study discontinua-
tion was withdrawal of consent. The main reason for transition
from prior oral AP treatment was patient’s wish (44%) followed
by lack of efficacy (24%), lack of compliance (23%), and lack of
tolerability (9%) with previous AP medication.
In both groups, the majority of patients were male (63.1%)
and had a diagnosis of schizophrenia, paranoid subtype
(78.6%). Noticeable baseline differences in recently diagnosed
compared with chronic patients were younger age, a higher
rate of paranoid subtype schizophrenia, lower baseline body
weight and BMI, and a lower rate of vascular disorders (parti-
cularly hypertension), metabolism and nutrition disorders. In
addition, most (83.3%) recently diagnosed patients had a
history of ≤3 psychiatric hospitalizations while more than
half (51.7%) of chronic patients had a history of ≥4 previous
psychiatric hospitalizations (Table 2).
Nearly two-thirds (61.2%) of recently diagnosed and
chronic patients had at least one co-morbidity at baseline.
The body systems for which ≥10% of patients overall reported
co-morbidities were psychiatric disorders (22.1%, of which the
most frequent were: insomnia, 8.1%; depression, 7.8%; anxiety,
3.9%), metabolism and nutrition disorders (15.3%), and ner-
vous system disorders (14.0%). Higher incidences (≥2% differ-
ence) of hepatobiliary disorders (3.4% vs. 0.8%), laboratory
tests (4.7% vs. 2.2%), psychiatric disorders (24.5% vs. 20.6%),
and skin and subcutaneous tissue disorders (3.9% vs. 1.7%)
were reported in patients who were recently diagnosed com-
pared with chronic patients, respectively. Other disorders of
body systems that were more frequently reported (≥2% dif-
ference) in chronic compared with recently diagnosed patients
included vascular disorders (11.4% vs. 4.7%), infections and
infestations (6.9% vs. 4.7%), gastrointestinal disorders (9.7% vs.
6.9%), and metabolism and nutrition disorders (19.2%
vs. 9.4%).
The mean modal PP1M maintenance doses (standard
deviation [SD]) (excluding the Day 1/Day 8 initiation regimen)
were numerically lower, but overall comparable for recently
diagnosed (98.5 [34.2] mg eq; 95% confidence interval [CI]
94.1, 102.9) and chronic patients (103.3 [32.9] mg eq; 95% CI
99.7, 106.9) (Table 2). The majority of patients received PP1M
according to the recommended initiation regimen on Day 1
(150 mg eq; 98.3% recently diagnosed, 99.2% chronic) and
Day 8 (100 mg eq; 97.8% recently diagnosed, 96.9% chronic).
Of those who did not receive the recommended initiation
regimen, most either missed their Day 8 dose (n = 15),
received a higher Day 8 dose (n = 8) after receiving the correct
Day 1 dose, or received a lower dose on Day 1 before receiv-
ing the correct dose on Day 8 (n = 6). Around half (51.5%) of
recently diagnosed and 46.4% of chronic patients required
only one maintenance dose adjustment after the third dose.
3.2 Efficacy outcomes
In total, 71.4% of all recently diagnosed patients and 59.2% of
all chronic patients showed a treatment response, as mea-
sured by a decrease of ≥20% in the PANSS total score at
Table 1. Patient disposition.
Recently diagnosed patients
(≤3 years)
Chronic patients
(>3 years)
Patients enrolled (n) 234 361
ITT population* (n) 233 360
↓ ↓
Most common reasons for early study discontinuation (≥2% in any group) (%)
Withdrawal of consent 6.4 12.5
Lost to follow-up 3.9 2.8
Adverse event 3.4 7.8
Lack of efficacy 3.0 2.2
*Patients who received at least one dose of study drug.
ITT: Intent-to-treat.
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endpoint (p = 0.0028 between groups, Fisher’s exact test).
Furthermore, over one-third (39.4%) of recently diagnosed
patients and nearly one-quarter (24.6%) of chronic patients
achieved ≥50% improvement in PANSS total score (p < 0.001
between groups, Fisher’s exact test). Mean PANSS total score
(SD) decreased from 72.6 (14.8) and 70.7 (14.4) at baseline to
57.5 (16.9) and 61.2 (18.7) at endpoint in recently diagnosed
and chronic patients, respectively, with a statistically signifi-
cant and clinically relevant improvement (SD; 95% CI of mean
change) observed in both recently diagnosed (−15.1 [15.6;
−17.1, −13.1]; p < 0.0001) and chronic patients (−9.6 [15.7;
−11.2; −8.0]; p < 0.0001) (change from baseline to endpoint;
between-group test, p < 0.0001) (Figure 1).
The changes from baseline to endpoint for recently diag-
nosed and chronic patients were statistically significant for
mean PANSS positive subscale, negative subscale, and gen-
eral psychopathology subscale score (Table 3) as well as
Marder factor scores (p < 0.0001, Wilcoxon signed-rank
test). At baseline, 69.9% of recently diagnosed and 67.1%
of chronic patients were rated as moderately, markedly, or
severely ill based on CGI-S score. At endpoint, the propor-
tion of patients in these categories decreased from baseline
by 36.7% and 28.1%, respectively (p < 0.0001 for both
groups, McNemar’s test). At Month 6 and endpoint, disease
severity was rated as much improved or very much
improved in 59.4% and 52.4% of recently diagnosed
patients compared with 48.6% and 38.0% in the chronic
group, respectively (CGI-C; p = 0.0320 and p = 0.0008
between groups, Fisher’s exact test) (Figure 2).
3.3 Subjective well-being, treatment satisfaction and
caregiver involvement
Measures of subjective patient well-being (SWN-S; p < 0.0001 for
both groups), treatment satisfaction (TSQM global satisfaction;
p < 0.0001 for both groups), sleep quality (p < 0.0001 for recently
diagnosed and p = 0.0346 for chronic patients), and daytime
drowsiness (p < 0.0001 for recently diagnosed and p = 0.0008
for chronic patients) also showed statistically significant improve-
ments from baseline to endpoint in both recently diagnosed and
Table 2. Patient demographics and dosing information.
Recently diagnosed
(≤3 years)
(n = 233)
Chronic (>3 years)
(n = 360)
Mean age, years (SD) 32.2 (10.3) 42.4 (11.0)
Mean age at diagnosis, years (SD) 32.0 (10.3) 29.5 (9.4)
Male, (%) 63.9 62.5
Schizophrenia subtype, n (%)
Paranoid 195 (83.7) 271 (75.3)
Disorganized 13 (5.6) 30 (8.3)
Catatonic 1 (0.4) 4 (1.1)
Undifferentiated 19 (8.2) 35 (9.7)
Residual 5 (2.1) 20 (5.6)
Mean baseline weight, kg (SD) 77.6 (17.1) 83.3 (17.8)
Mean BMI, kg/m2 (SD) 26.2 (5.7) 28.6 (5.9)
Patients with ≥1 co-morbidity, %* 60.9 61.4
Relevant co-morbidities reported in ≥5% of patients in any group and >4% difference between groups, n (%)
Metabolism and nutrition disorders 22 (9.4) 69 (19.2)
Vascular disorders 11 (4.7) 41 (11.4)
Hypertension 10 (4.3) 31 (8.6)
Number of patients with previous psychiatric hospitalizations, n (%)
None 59 (25.3) 54 (15.0)
1–3 135 (57.9) 120 (33.3)
≥4 39 (16.7) 186 (51.7)
PP1M dosing
Patients receiving PP1M initiation regimen at Day 1 and Day 8 according to protocol, n (%)† 219 (94.0) 338 (93.9)
Mean modal PP1M maintenance dose, mg eq (SD)‡ 98.5 (34.2) 103.3 (32.9)
Last PP1M maintenance dose received, n (%) of patients
50 mg eq 26 (11.2) 27 (7.5)
75 mg eq 78 (33.5) 90 (25.0)
100 mg eq 71 (30.5) 140 (38.9)
150 mg eq 58 (24.9) 103 (28.6)
Relevant co-medications
Patients using benzodiazepines, n (%)
At baseline 43 (18.5) 95 (26.4)
Newly initiated during study 42 (18.0) 83 (23.1)
At endpoint 39 (16.7) 84 (23.3)
At 6 months for completers 25 (13.8) 60 (23.0)
Patients using anticholinergics, n (%)
At baseline 28 (12.0) 39 (10.8)
Newly initiated during study 22 (9.4) 26 (7.2)
At endpoint 18 (7.7) 28 (7.8)
At 6 months for completers 13 (7.2) 18 (6.9)
*Individual patients can be labelled for >1 co-morbidity.
†The recommended initiation regimen was PP1M 150 mg eq on Day 1 and 100 mg eq on Day 8 given in the deltoid muscle.
‡Excluding the initiation regimen (Day 1/Day 8).
BMI: body mass index; PP1M: once-monthly paliperidone palmitate; SD: standard deviation.
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chronic patients (Table 4). There were no significant between-
group differences for mean change in SWN-S total score and no
between-group differences in TSQM total or individual domain
scores except for ‘convenience’ for which the mean change from
baseline to endpoint was significantly greater in recently diag-
nosed compared with chronic patients (p < 0.05). Statistically
significant increases from baseline to endpoint in all four TSQM
domain scores (effectiveness, side effects, convenience, and glo-
bal satisfaction) were observed in both groups, indicating
improved satisfaction with treatment compared with baseline
medication. Sleep quality and daytime drowsiness were signifi-
cantly better in recently diagnosed compared with chronic
patients (p < 0.05 for both).
There was a statistically significant (p = 0.0113) reduction
in the IEQ total score from baseline to endpoint in the total
population of non-acute patients group as a whole, indicat-
ing a reduction in carer burden during the study.
Reductions in the IEQ total score were also observed in
recently diagnosed and chronic patients but these changes
did not reach statistical significance; this may be partly due
Figure 1. Mean PANSS total score over time (efficacy ITT population).
***p < 0.0001 vs. baseline.
†††p < 0.0001 for mean change from baseline in PANSS total score for recently diagnosed vs. chronic patients.
Error bars represent 95% confidence intervals.
BL: baseline; ITT: intent-to-treat; PANSS: Positive and Negative Syndrome Scale.
Table 3. Efficacy outcome (efficacy ITT population)*.
Recently diagnosed (≤3 years)
(n = 231)
Chronic (>3 years)
(n = 358)
Mean PANSS positive subscale score, (SD)
Baseline 15.6 (4.8) 15.4 (5.0)
Endpoint 12.1 (4.7) 13.1 (5.4)
Mean change from baseline to endpoint −3.6 (4.9) −2.3 (4.9)
95% CI of mean change; p value† −4.2, −2.9; <0.0001 –2.8, −1.8; <0.0001
Change from baseline to endpoint p value between subgroup test‡ 0.0010
Mean PANSS negative subscale score, (SD)
Baseline 20.4 (5.3) 20.1 (5.5)
Endpoint 16.0 (5.5) 17.2 (6.1)
Mean change from baseline to endpoint −4.4 (5.1) −2.9 (5.5)
95% CI of mean change; p value† −5.1, −3.8; <0.0001 –3.4, −2.3; <0.0001
Change from baseline to endpoint p value between subgroup test‡ 0.0003
Mean PANSS general psychopathology score, (SD)
Baseline 36.6 (8.4) 35.2 (7.7)
Endpoint 29.5 (8.6) 30.8 (9.6)
Change from baseline to endpoint −7.1 (8.4) −4.4 (8.2)
95% CI of mean change; p value† −8.2, −6.0; <0.0001 −5.3, −3.6; <0.0001
Change from baseline to endpoint p value between subgroup test‡ 0.0001
*Only patients with a valid baseline measurement and at least one valid follow-up assessment were included.
†Within-group difference was tested using the Wilcoxon signed-rank test.
‡Between-group difference was tested using the Wilcoxon two-sample test.
CI: confidence interval; ITT: intent-to-treat; PANSS: Positive and Negative Syndrome Scale; SD: standard deviation.
EXPERT OPINION ON PHARMACOTHERAPY 1047
D
ow
nl
oa
de
d 
by
 [S
em
me
lw
eis
 U
niv
ers
ity
 B
ud
ap
es
t] 
at 
23
:45
 31
 M
ay
 20
16
 
to lack of statistical power because of the small number of
carers assessed.
3.4 Functioning outcomes
From baseline to endpoint, the mean PSP total score increased
from 59.2 to 67.7 in recently diagnosed patients and from 57.4 to
65.0 in chronic patients (p < 0.0001 for both groups, Wilcoxon
signed-rank test). There was no significant between-group
change from baseline in PSP total score (p = 0.27, Wilcoxon
two-sample test). The proportion of patients with mild or no
functional impairment (PSP total score of 71–100) increased
from 15.1% at baseline to 47.1% at endpoint (recently diag-
nosed) and from 15.5% at baseline to 36.7% at endpoint
Figure 2. CGI–C according to proportion of patients by category over time (efficacy ITT population).
*p = 0.0320; †p = 0.0008 between-group comparison, Fisher’s exact test.
CGI–C: Clinical Global Impression–Change; ITT: intent-to-treat.
Table 4. Selected secondary endpoints*.
Recently diagnosed (≤3 years) Chronic (>3 years)
Mean SWN-S total score, n 211 310
Baseline, (SD) 80.7 (16.7) 79.7 (17.6)
Endpoint, (SD) 86.6 (17.7) 84.7 (17.1)
Mean change from baseline to endpoint, (SD) 5.9 (16.6) 5.0 (15.0)
95% CI; p value† 3.6, 8.2; <0.0001 3.4, 6.7; <0.0001
Change from baseline to endpoint p value between subgroup test‡ NS
Mean TSQM total global satisfaction score, n 195 299
Baseline, (SD) 56.6 (20.3) 55.4 (22.4)
Endpoint, (SD) 68.3 (23.4) 62.9 (26.0)
Mean change from baseline to endpoint (SD) 11.7 (27.9) 7.5 (29.7)
95% CI; p value† 7.7, 15.6; <0.0001 4.1, 10.9; <0.0001
Change from baseline to endpoint p value between subgroup test‡ NS
§Mean quality of sleep score, n 229 353
Baseline, (SD) 6.9 (2.4) 6.7 (2.6)
Endpoint, (SD) 7.7 (2.2) 7.0 (2.4)
Mean change from baseline to endpoint, (SD) 0.8 (2.6) 0.3 (2.8)
95% CI; p value† 0.5, 1.1; <0.0001 0.0, 0.6; 0.0346
Change from baseline to endpoint p value between subgroup test‡ 0.0397
¶Mean drowsiness score, n 229 353
Baseline, (SD) 4.0 (2.8) 3.9 (2.9)
Endpoint, (SD) 2.8 (2.7) 3.3 (2.8)
Mean change from baseline to endpoint, (SD) −1.3 (3.4) −0.6 (3.4)
95% CI; p value† −1.7, −0.8; <0.0001 −1.0, −0.2; 0.0008
Change from baseline to endpoint p value between subgroup test‡ 0.0118
*Only patients with a valid baseline measurement and at least one valid follow-up assessment were included.
†Within-group difference was tested using the Wilcoxon signed-rank test.
‡Between-group difference was tested using the Wilcoxon two-sample test.
§A higher score indicates improvements in the quality of sleep.
¶A lower score indicates improvements in the level of drowsiness.
CI: confidence interval; NS: not significant; SD: standard deviation; SWN-S: Subjective Well-being under Neuroleptics (Short form); TSQM: Treatment Satisfaction
Questionnaire for Medication.
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(chronic) (p < 0.0001 for both groups, McNemar’s test) and
differed significantly between groups (p = 0.0058, Fisher’s exact
test) (Figure 3).
Illness-related disabilities of activity and participation in
Mini-ICF-APP were significantly lower in recently diagnosed
compared with chronic patients at baseline (p < 0.01
between-groups comparison, Wilcoxon two-sample test) and
mean (SD) Mini-ICF-APP total scores improved significantly
from baseline, including all domains of activity and participa-
tion, to endpoint in both recently diagnosed (18.7 [7.6]–14.6
[8.8] [p < 0.0001]) and chronic patients (20.6 [7.9]−16.7 [8.8]
[p < 0.0001]) (Figure 4A and 4B). The mean change from
baseline was not statistically significantly different between
groups.
3.5 Tolerability and safety
In the safety ITT population, 61.4% of recently diagnosed and
58.6% of chronic patients had at least one TEAE; 12.0% and
17.2% had at least one serious TEAE, respectively. Most TEAEs
were rated as mild or moderate in intensity (93.1% in both
patient groups). Thirteen (5.6%) recently diagnosed patients
and 29 (8.1%) chronic patients had at least one TEAE that led
to early termination of the study. TEAEs reported in ≥5% of
subjects in at least one group are summarized in Table 5.
Although there were no obligatory protocol-based labora-
tory tests during this pragmatic study; at least one potentially
prolactin-related TEAE was reported by 3.0% (n = 7) of
recently diagnosed patients and 3.1% (n = 11) of chronic
Figure 3. Functioning outcomes in non-acute schizophrenia patients. Changes in frequency distribution by PSP category over time in recently diagnosed and
chronic patients.
PSP: Personal and Social Performance
Figure 4. Functioning outcomes in non-acute schizophrenia patients: Mini-ICF-APP domain scores* at baseline and endpoint for recently diagnosed (A, n = 218) and
chronic (B, n = 325) patients.
*Change from baseline to Month 6, p < 0.0001 for all domains in both groups.
Mini-ICF-APP: Mini International Classification of Functionality, Disability and Health (ICF) Rating for Activity and Participation Disorders in Psychological Illnesses.
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patients, and increased prolactin levels were reported in one
patient in each group. The mean (SD) ESRS total score at
baseline was 2.0 (3.4) for recently diagnosed and 3.4 (5.76)
for chronic patients. The mean change in ESRS (SD) from
baseline to endpoint was −0.9 (3.4) for recently diagnosed
and −1.4 (4.5) for chronic patients (p < 0.0001 for both
groups). There was a reduction in the proportion of patients
receiving benzodiazepines and anticholinergics from base-
line to endpoint and end of study in both recently diagnosed
and chronic patients (Table 2). The mean weight change (SD)
from baseline to endpoint was 1.4 (5.0) kg (95% CI 0.8, 2.1)
for recently diagnosed and 1.0 (5.0) kg (95% CI 0.4, 1.6) for
chronic patients. Overall, 18% of recently diagnosed patients
and 13.7% of chronic patients had a weight gain of ≥7% at
endpoint. At baseline, 89.5% (n = 187) of recently diagnosed
and 92.0% (n = 287) of chronic patients were assessed as
abstinent using the CRSUS; while at endpoint 91.4% (n = 191)
of recently diagnosed and 94.2% (n = 294) of chronic patients
were assessed as abstinent.
4. Discussion
In this post hoc analysis of recently diagnosed and chronic
non-acute but symptomatic patients with schizophrenia,
both groups showed clinically relevant improvement of
their symptoms; yet a significantly greater improvement
was observed in the recently diagnosed group. The change
in PANSS total score, PANSS Marder factors and PANSS sub-
scales were all statistically significantly greater in recently
diagnosed patients compared with chronic patients, consis-
tent with the established view that newly and more recently
diagnosed patients tend to be more responsive to APs com-
pared with multiple-episode patients.[36,37] These results are
of particular interest since, according to current guidelines,
LATs are largely reserved for patients with recurrent relapses
related to nonadherence.[1,8] However, it should be noted
that guidelines are based primarily on RCTs, and patients
included in RCTs are not fully representative of the whole
spectrum of patients encountered in clinical practice.
Measurement of the comparative effectiveness of APs has
been shown to be sensitive to study design [13] and there-
fore more pragmatic trials are recommended for the evalua-
tion of treatment efficacy in a naturalistic clinical practice
setting.[38] As such, treatment guidelines do not always
offer the level of detail that might be expected and/or
required, particularly around issues of illness management
in newly and more recently diagnosed patients,[39,40] high-
lighting a need for more open-label or double-blind RCTs in
early phases of schizophrenia.[40] A pertinent example is the
current study, in which a more diverse population of patients
with schizophrenia (with higher rates of co-morbidities, sub-
stance abuse, and/or comedications) was included in the
study population to provide data in a more representative
setting.
The results from this analysis are in line with a prospective,
single-site, open-label study in patients with recent-onset psycho-
sis who were treated with risperidone LAT (RLAT) over 2 years.
[4,41] A clinical response of at least 20% reduction in PANSS total
scores was obtained by 92% (46/50) of patients, and a reduction of
at least 50% was obtained by 84% (42/50) of patients,[41] while
84.8% of patients achieved remission.[4] Thus, the results from the
current study provide further evidence that a substantial propor-
tion of patients at an early stage of schizophrenia who receive LAT
are able to achieve considerable and sustained symptomatic and
functional improvement. A post hoc analysis of a 13-week, rando-
mized, double-blind, double-dummy comparative study of PP1M
(n = 161) and RLAT (n = 173) in adults with schizophrenia, which
focused specifically on a subset of patients with recently diag-
nosed schizophrenia (≤5 years before study entry), showed that
the tolerability (including rates of EPMS and prolactin-related
TEAEs) and efficacy of PP1M and RLAT were generally similar
over 13 weeks.[42] While the recently diagnosed patients
described in the current study had a lower baseline PANSS total
score than those in this 13-week study, they achieved a similar
reduction at study endpoint, highlighting that further clinically
relevant symptom improvements are possible, even in this more
stabilized population. Baseline value andmean change from base-
line in PSP total score were also similar between studies.
Furthermore, in a study by Lieberman et al., data collected over
5 years suggested that patients with schizophrenia should be
treated as early as possible to improve long-term prognosis.[36]
Taken together, these results support the view that patients
should be treated as early as possible in the course of the disorder
for better long-term outcomes.
Patients in this study were non-acute but symptomatic and
considered as stable by their treating physician for at least
1 month prior to enrolment. Nevertheless, 39.4% of recently
diagnosed patients and 24.6% of chronic patients achieved
a ≥50% improvement in PANSS total score. These data are
clinically relevant since this result demonstrates that continu-
ous effective treatment in patients who are considered clini-
cally stable still offers the opportunity for further clinically
relevant symptom improvement.
Higher incidences of weight gain and depression were
reported in recently diagnosed compared with more chronic
patients. The greater incidence of weight gain in recently
diagnosed patients is in line with another study of early
schizophrenia in which most weight gain occurred within
the first 3 to 6 months of treatment [43] as well as data
showing that patients with a higher baseline BMI gain less
weight than those with a lower BMI.[44] Moreover, the
finding that a relatively higher proportion of recently diag-
nosed patients reported depression over the study period
Table 5. TEAEs occurring in ≥5% of patients in any group (safety ITT
population).
Recently diagnosed (≤3 years)
(n = 233)
Chronic (>3 years)
(n = 360)
Number of patients (%)
Injection-site pain 30 (12.9) 43 (11.9)
Insomnia 23 (9.9) 28 (7.8)
Anxiety 15 (6.4) 25 (6.9)
Headache 14 (6.0) 19 (5.3)
Akathisia 13 (5.6) 15 (4.2)
Somnolence 12 (5.2) 14 (3.9)
Weight increased 12 (5.2) 7 (1.9)
Depression 12 (5.2) 6 (1.7)
Psychotic disorder 11 (4.7) 25 (6.9)
ITT: intent-to-treat; TEAEs: treatment-emergent adverse events.
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(5.2% vs. 1.7% of chronic patients) is in line with depressive
symptoms being frequent among newly diagnosed patients
at baseline but decreasing during follow-up periods of up to
10 years.[45] Overall, in the present study, clinically relevant
TEAEs such as EPMS, sedation, potentially prolactin-related
TEAEs, and weight gain with PP1M were low and consistent
with the randomized controlled studies,[46–48] which sug-
gests that PP1M is also generally well tolerated in a patient
population more representative of routine clinical practice
with higher rates of co-morbidities, co-medications, and
substance abuse.
Patients with schizophrenia are known to have a shorter
life expectancy than the general population;[49,50] likely
linked to the increased incidence of cardiovascular risk fac-
tors as well as metabolic co-morbidities reported in these
patients.[51] Consistent with the latter observation, chronic
patients in the current study population had a greater
incidence of metabolic and vascular disorders at baseline.
Early initiation of continuous treatment may benefit
patients, as a lack of AP treatment has been associated
with greater all-cause mortality.[50]
Despite the potential advantages of using LAT demon-
strated in this and other studies,[12,14,16,17] they are consid-
ered underused in practice [40] and negative attitudes
towards their use early in the treatment of schizophrenia
among psychiatrists are common.[52] Furthermore, there is
some debate in relation to the use of LAT in the early phases
of schizophrenia.[9] Yet, recommendations for their use earlier
in the disease course are emerging, not least during the
critical period of the first 2 to 5 years following diagnosis
[20] and as maintenance treatment following the first episode
of psychosis.[19]
These were post hoc analyses and should therefore be
considered exploratory in nature. Study limitations include
the unblinded treatment and the lack of a comparator
group, resulting in a potential for reporting bias.
Therefore, these data do not provide a head-to-head com-
parison between treatments but suggest that suboptimal
treatment with one AP does not predict failure with other
APs, including PP1M, and that recently diagnosed patients
may show a higher treatment response than more chronic
patients. Comparison between treatments was not the pri-
mary aim of this pragmatic trial, which was designed to
capture data in a setting mirroring daily clinical practice,
not normally achieved in RCTs. Nevertheless, the method
used in this study is consistent with current standards used
in clinical trials and therefore allows for some indirect com-
parisons with data from interventional studies of a similar
design. In addition, the present study did not exclude
patients with current substance use or abuse, with the
exception of intravenous drug use; this is in contrast to
the pivotal randomized controlled studies in PP1M that
excluded patients with a DSM-IV diagnosis of active sub-
stance dependence within 3 months prior to screening.
[47,48,53] Nonetheless, rates of alcohol/substance use in
the current group of patients were low, and it cannot be
ruled out that psychiatrists selected patients who they felt
would be most likely to complete the study.
5. Conclusions
Data from the current study demonstrate that recently diag-
nosed patients treated with PP1M had a significantly higher
treatment response and better functioning, as assessed by the
PSP total score, compared with more chronic patients. These
data support current discussions that earlier continuous and
effective AP treatment may be associated with better out-
comes in patients with schizophrenia.
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